Recursion Pharmaceuticals announced the top-line results of its SYCAMORE trial for REC-994 in patients with cerebral cavernous malformation and provided financial information regarding its proposed acquisition of Exscientia, which is expected to result in Recursion stockholders owning approximately 74% and Exscientia shareholders owning about 26% of the combined company post-transaction.